MitoRx Therapeutics will present preclinical data at EASD 2025 on MTRX31, a small molecule that reduces body weight and fat mass in diet-induced obese mice by shifting fuel use from fat to carbohydrate oxidation rather than suppressing appetite. The company reports greater and more durable weight loss than tirzepatide at the doses tested, with lean mass preserved. All figures remain unpublished, and the study was conducted at thermoneutrality to remove cold-induced energy expenditure as a confounder.
Key Points
- MTRX31 restores mitochondrial fuel switching without suppressing appetite
- Mice lost weight and fat mass while preserving lean tissue
- Company-reported advantage over tirzepatide lacks published figures
Longevity Analysis
The target population — visceral adiposity, insulin resistance, ectopic fat deposition and impaired mitochondrial function — maps directly onto the conditions that shorten healthspan: steatotic liver disease, type 2 diabetes and atherosclerotic cardiovascular disease. A compound that restores the capacity to alternate between fat and carbohydrate as fuel addresses a defect in cellular energy handling rather than the hunger signal, and preservation of lean mass matters for the structural resilience that determines function in later decades. Preclinical rodent data at thermoneutrality is a methodologically cleaner starting point than most, but the absence of dose, duration and effect-size figures means the claim cannot yet be evaluated.
Original published by Longevity.Technology, by Kyle Umipig.